|Project Title||Development and Evaluation of a Global Propensity Score for Data Mining with Tree-Based Scan Statistics|
Friday, August 10, 2018
The aims of this methods project are to develop and evaluate candidate global propensity scores for application with the propensity score cohort matched design and tree-based scan statistics. The examples used in this project are for methods development purposes and are not part of a regulatory evaluation of any medical product or safety issue.
The Workgroup will compare the relative performance of candidate global propensity scores which could be applied generally in cohort studies involving tree-based scan statistics by evaluating 4 case studies for drug safety signal detection. The selected case studies have well characterized safety profiles. After evaluating the relative performance of candidate global propensity scores, the Workgroup will conduct clinical and epidemiologic review of alerts observed with the pre-specified primary global propensity score to adjust for confounding.
The Workgroup will use the CDER-curated Multi-Level Clinical Classification Software (MLCCS) outcome tree. This tree contains thousands of hierarchically grouped adverse events and is based on International Classification of Diseases 9th edition (ICD-9-CM) codes. Further curation may occur for specific drug evaluation examples based on the outcomes that are closely related to the reason for prescribing the drug.
This protocol was posted for public comment from August 10, 2018 through September 7, 2018. The public comment period is now closed. A revised version was approved for implementation by FDA on September 26. A log of changes is included in the revised protocol (v2).
Shirley V. Wang PhD, ScM, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA;
Danijela Stojanovic PharmD, PhD, Office of Surveillance and Epidemiology, Center for Drug and Evaluation Research, US Food and Drug Administration, Silver Spring, MD
Elande Baro PhD; Rima Izem PhD; Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
Efe Eworuke PhD; Rita Ouellet-Hellstrom PhD, MPH; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
Joshua J. Gagne PharmD, ScD; Sushama Kattinakere MBBS, MSPH: Martin Kulldorff PhD; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Sandra DeLuccia MPH, Judith C. Maro PhD; Ella Pestine MPH; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA